WASHINGTON — The Senate on Thursday, without fanfare or controversy, approved legislation that will keep many Food and Drug Administration operations running and deliver a significant win to the pharmaceutical industry.

Lawmakers voted 94-1 to approve the so-called “user fee agreements” that govern how much private drug and device makers pay in fees to support the approval and oversight processes at the FDA. Sen. Bernie Sanders (I-Vt.) was the only no vote.